The abstract is read at the publisher; the summary is JClub's.
KW-2449, an orally bioavailable FLT3 inhibitor, penetrates the blood-brain barrier and increases KCC2 expression for up to 24 hours, reducing seizure susceptibility in kainic acid–induced mice.
- Why it matters: About one-third of people with epilepsy do not respond to current anti-seizure medications, and FLT3’s neuronal role is largely unexplored despite its expression in the brain.
- What they did: Using functional genomics in mouse primary neurons and human stem cell-derived neurons, the study mapped FLT3i-driven transcriptional programs and used a CRISPR/Cas9 screen to identify FLT3-responsive transcription factor networks.
- The result: The FLT3-responsive networks linked to epigenetic remodeling and neuroinflammatory signaling, and in vivo KW-2449 elevated KCC2 and significantly lowered seizure susceptibility in the kainic acid mouse model.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.